Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD-DPP4 study of once-weekly omarigliptin vs daily DPP-4 inhibitors on treatment burden and QOL in type 2 diabetes
jRCTs031200437Completed
- Sponsor
- Japan Society for Patient Reported Outcome
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of omarigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Japan Society for Patient Reported Outcome. Primary endpoint: Change in DTBQ score. Started Apr 2021; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031200437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200437.